Predictors of success and failure in achieving glycemic control targets in patients with type 2 diabetes on basal insulin: review of the real-world evidence studies
Basal insulin (BI) is the main therapeutic option for patients with type 2 diabetes (T2D) who have not reached glycemic targets on oral antidiabetic drugs and/or glucagon-like peptide-1 receptor agonists. The results of epidemiological studies indicate that the majority of patients with T2D do not a...
Saved in:
| Main Author: | V. V. Klimontov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2023-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12950 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01) -
Characteristics of insulin prescriptions and their association with glycemic control in adults with type 2 diabetes mellitus
by: Helen Chen, et al.
Published: (2025-07-01) -
Change in the Character of Insulin Autoantibody Over Time in a Patient of Exogenous Insulin Autoimmune Syndrome
by: Shakun Chaudhary, et al.
Published: (2025-04-01) -
Investigating Real-World Stability and Sterility of in-Use Insulin-An Urgent Public Health Concern. In Sub-Saharan Africa
by: Kimaro E, et al.
Published: (2025-08-01) -
Correlation between Insulin antibodyand HbA1c in Diabetes Mellitus
by: Joumana Sharad, et al.
Published: (2024-12-01)